Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study.

Inés Suárez-GarcíaCristina MorenoMarta Ruiz-AlgueróMaría Jesús Pérez-ElíasMarta NavarroMarcos Díez MartínezPompeyo VicianaLaura Pérez-MartínezMiguel GórgolasConcha AmadorMiguel Alberto de ZárragaInma Jarrínnull null

Published in: AIDS research and therapy (2020)

EVG/COB/TFV/FTC + DRV was well tolerated and effective in treatment-experienced patients with undetectable viral load as a simplification strategy, allowing once-daily, two-pill regimen with three antiretroviral drug classes. Effectiveness was low in patients with detectable viral loads.

Keyphrases

randomized controlled trial
clinical practice
end stage renal disease
systematic review
chronic kidney disease
clinical trial
ejection fraction
newly diagnosed
human immunodeficiency virus
hiv infected
prognostic factors
study protocol
hiv aids
replacement therapy
patient reported outcomes
patient reported